Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on Kymera Therapeutics and keeping the price target at $60.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Fein has given his Buy rating due to a combination of factors surrounding Kymera Therapeutics’ recent developments and future prospects. The company’s STAT6 degrader, KT-621, is highlighted as a significant near-term value driver, with promising Phase 1b data expected to be released in the fourth quarter of 2025. The completion of the BroADen Phase 1b study ahead of schedule, along with the selection of doses for upcoming Phase 2b trials in atopic dermatitis and asthma, underscores the potential of KT-621 in addressing these conditions.
Furthermore, the early data from healthy volunteers and moderate-to-severe atopic dermatitis patients show encouraging biomarker and clinical readouts, suggesting that KT-621 could meet or exceed efficacy benchmarks set by existing treatments like dupilumab. The anticipated proof-of-concept trials with once-daily dosing in the 50–100 mg range further support the potential for positive outcomes. These factors combined with the company’s strategic planning and clean toxicology results contribute to Fein’s optimistic outlook and Buy rating for Kymera Therapeutics.
Fein covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Biogen, and Kymera Therapeutics. According to TipRanks, Fein has an average return of 9.5% and a 46.76% success rate on recommended stocks.
In another report released today, Wells Fargo also reiterated a Buy rating on the stock with a $53.00 price target.